Main therapeutic and rehabilitation actions in patients with congenital insensitivity to pain

Introduction: congenital insensitivity to pain is a hereditary whose main characteristic is absolute analgesia to pain. Objective: to describe the main existing therapeutic actions for patients with congenital insensitivity to pain in its diverse subtypes. Method: a total of 30 scientific articles were reviewed, which met the inclusion criteria. Databases such as Medline (PubMEd) and SciELO were consulted. All studies with limited or insufficient quality of evidence, or those in which full-text information was not available, were excluded. Development: at present, studies related to the use of bisphosphonates and minimal scale surgical interventions for the reduction of bone complications of the disease and the use of opioid receptor antagonists such as naloxone with the aim of reducing analgesia in these patients stand out. It also highlights research related to nerve growth factor in conjunction with the expression of the high affinity tyrosinkinase receptor for this factor, which produces a relative improvement with respect to the absolute analgesia that is evidenced in this disease. Conclusions: although the mechanisms by which it is established are not yet fully clarified, there is strong scientific evidence that supports a central role of genetics in the etiology of the disease. There is no highly effective therapeutic alternative in the current medical literature; that is why the basic role of these actions is based on prevention, education and interdisciplinary treatment.